Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.

about

Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.

Item

http://www.wikidata.org/entity/Q38769344

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Healthcare costs among men wit ...... integrated healthcare system.

@en

type

Item

label

Healthcare costs among men wit ...... integrated healthcare system.

@en

prefLabel

Healthcare costs among men wit ...... integrated healthcare system.

@en

P1476

Healthcare costs among men wit ...... integrated healthcare system.

@en

P2093

David Morgenstern

http://www.w3.org/2001/XMLSchema#string

Eric Meadows

http://www.w3.org/2001/XMLSchema#string

Furaha Kariburyo

http://www.w3.org/2001/XMLSchema#string

I-Ning Elaine Cheng

http://www.w3.org/2001/XMLSchema#string

Igor Asner

http://www.w3.org/2001/XMLSchema#string

John Danella

http://www.w3.org/2001/XMLSchema#string

Lin Xie

http://www.w3.org/2001/XMLSchema#string

Lisa Wang

http://www.w3.org/2001/XMLSchema#string

Yuexi Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Overdiagnosis and overtreatment in cancer: an opportunity for improvement

Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.

Guideline for the management of clinically localized prostate cancer: 2007 update.

Economic burden of cancer in the United States: estimates, projections, and future research

Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.

Cumulative cost pattern comparison of prostate cancer treatments.

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.

Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.

P304

825-831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2017.1333512

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28534659

http://www.w3.org/2001/XMLSchema#string